DE60219940D1 - Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie - Google Patents

Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie

Info

Publication number
DE60219940D1
DE60219940D1 DE60219940T DE60219940T DE60219940D1 DE 60219940 D1 DE60219940 D1 DE 60219940D1 DE 60219940 T DE60219940 T DE 60219940T DE 60219940 T DE60219940 T DE 60219940T DE 60219940 D1 DE60219940 D1 DE 60219940D1
Authority
DE
Germany
Prior art keywords
irbesartan
preventing
treating pulmonary
pulmonary hypertonia
hypertonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60219940T
Other languages
English (en)
Other versions
DE60219940T2 (de
Inventor
Sylvie Cosnier-Pucheu
Dino Nisato
Alain Roccon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Application granted granted Critical
Publication of DE60219940D1 publication Critical patent/DE60219940D1/de
Publication of DE60219940T2 publication Critical patent/DE60219940T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60219940T 2001-10-26 2002-10-09 Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie Expired - Lifetime DE60219940T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0113936 2001-10-26
FR0113936A FR2831446B1 (fr) 2001-10-26 2001-10-26 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
PCT/FR2002/003439 WO2003035062A1 (fr) 2001-10-26 2002-10-09 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire

Publications (2)

Publication Number Publication Date
DE60219940D1 true DE60219940D1 (de) 2007-06-14
DE60219940T2 DE60219940T2 (de) 2008-01-17

Family

ID=8868812

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60219940T Expired - Lifetime DE60219940T2 (de) 2001-10-26 2002-10-09 Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie

Country Status (24)

Country Link
US (2) US20040242567A1 (de)
EP (1) EP1441723B1 (de)
JP (1) JP4542777B2 (de)
CN (1) CN100418526C (de)
AT (1) ATE361071T1 (de)
AU (1) AU2002350832B2 (de)
BR (1) BR0213479A (de)
CA (1) CA2461625C (de)
CY (1) CY1106746T1 (de)
DE (1) DE60219940T2 (de)
DK (1) DK1441723T3 (de)
EA (1) EA007952B1 (de)
ES (1) ES2286304T3 (de)
FR (1) FR2831446B1 (de)
HU (1) HUP0401633A3 (de)
IL (2) IL161116A0 (de)
IS (1) IS2849B (de)
MX (1) MXPA04003910A (de)
NO (1) NO332313B1 (de)
NZ (1) NZ532130A (de)
PL (1) PL209263B1 (de)
PT (1) PT1441723E (de)
WO (1) WO2003035062A1 (de)
ZA (1) ZA200402696B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation
CN100367959C (zh) * 2006-08-29 2008-02-13 陈俊云 一种含有依贝沙坦的药物
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
WO2022198264A1 (en) * 2021-03-23 2022-09-29 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
EP1106210A3 (de) 1999-12-07 2003-12-03 Pfizer Products Inc. Zusammensetzungen, für die Behandlung von diabetischen Komplikationen, welche Aldosereductasehemmern und antihypertensive Mitteln enthalten

Also Published As

Publication number Publication date
US20090247510A1 (en) 2009-10-01
IL161116A0 (en) 2004-08-31
IS7200A (is) 2004-03-29
ES2286304T3 (es) 2007-12-01
EP1441723B1 (de) 2007-05-02
JP4542777B2 (ja) 2010-09-15
FR2831446B1 (fr) 2004-03-05
US8088827B2 (en) 2012-01-03
ZA200402696B (en) 2005-06-29
PL209263B1 (pl) 2011-08-31
FR2831446A1 (fr) 2003-05-02
MXPA04003910A (es) 2004-07-23
CA2461625A1 (en) 2003-05-01
PL368737A1 (en) 2005-04-04
AU2002350832B2 (en) 2006-11-30
DE60219940T2 (de) 2008-01-17
WO2003035062A1 (fr) 2003-05-01
CY1106746T1 (el) 2012-05-23
DK1441723T3 (da) 2007-09-10
EA200400438A1 (ru) 2004-10-28
IS2849B (is) 2013-09-15
NO332313B1 (no) 2012-08-27
BR0213479A (pt) 2004-11-03
EP1441723A1 (de) 2004-08-04
ATE361071T1 (de) 2007-05-15
HUP0401633A2 (hu) 2004-12-28
EA007952B1 (ru) 2007-02-27
JP2005506369A (ja) 2005-03-03
NO20041732L (no) 2004-07-23
IL161116A (en) 2010-12-30
CA2461625C (en) 2011-07-05
CN100418526C (zh) 2008-09-17
HUP0401633A3 (en) 2009-06-29
PT1441723E (pt) 2007-07-26
CN1610548A (zh) 2005-04-27
US20040242567A1 (en) 2004-12-02
NZ532130A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CY1106746T1 (el) Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
ATE271865T1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
ATE525073T1 (de) Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE60329326D1 (de) Tace inhibitoren
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60214152D1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
DE50302552D1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE50306258D1 (de) Topische verwendung von diuretika zur behandlung von schwellungen
DE60321377D1 (de) Verwendung von levocetirizin zur behandlung von persistierender allergischer rhinitis
ATE341322T1 (de) Verwendung von aminomethyl chromanen zur behandlung der nebenwirkungen von neuroleptika

Legal Events

Date Code Title Description
8364 No opposition during term of opposition